治疗前[⁶⁸Ga]-PSMA-11 PET/CT预测转移性肾细胞癌患者对免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗的反应
本回顾性研究纳入108例转移性肾细胞癌患者,治疗前接受[⁶⁸Ga]-PSMA-11 PET/CT,随后接受酪氨酸激酶抑制剂联合免疫检查点抑制剂一线治疗,按RECIST 1.1评估疗效。累积标准化摄取值-体积直方图曲线下面积(AUC-CSH)、最大标准化摄取值(SUVmax)及PD-L1状态为治疗反应的独立预测因子;三者联合模型的AUROC为0.880,显著高于各单独指标。
要点
- 治疗前[⁶⁸Ga]-PSMA-11 PET/CT的AUC-CSH(aOR 8.358,P=0.002)与SUVmax(aOR 1.092,P=0.024)是转移性肾细胞癌一线TKI联合ICI治疗反应的独立预测因子。
- AUC-CSH、SUVmax与PD-L1状态联合模型AUROC 0.880(95%CI 0.804-0.935),高于AUC-CSH单独(0.812,P=0.020)、SUVmax单独(0.757,P=0.031)及PD-L1状态单独(0.637,P<0.001)。
- 108例中CR 12例(11.1%)、PR 24例(22.2%)、SD 45例(41.7%)、PD 27例(25.0%)。
核心结论
- 治疗前[⁶⁸Ga]-PSMA-11 PET/CT的AUC-CSH和SUVmax是转移性肾细胞癌患者接受TKI联合ICI治疗反应的独立预测因子;与PD-L1状态联合可能改善患者分层,并有助于治疗开始前的临床决策。
研究设计与样本
- 回顾性研究,纳入108例转移性肾细胞癌患者(年龄69.4±6.2岁,男性38例),2019年1月至2023年3月接受治疗前[⁶⁸Ga]-PSMA-11 PET/CT及TKI联合ICI治疗,以RECIST 1.1评估治疗反应。
诊断标准与关键数值
- 治疗反应定义为完全缓解(CR)或部分缓解(PR);采用单因素及多因素logistic回归筛选独立预测因子,ROC曲线评估预测效能。
临床应用与阅片要点
- 原文结论指出,AUC-CSH与SUVmax联合PD-L1状态可能改善患者分层,并有助于治疗开始前的临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to investigate the feasibility of pretreatment ⁶⁸Ga-labeled prostate-specific membrane antigen-11 ([⁶⁸Ga]-PSMA-11) PET/CT for predicting treatment response in patients with metastatic renal cell carcinoma (mRCC) undergoing first-line therapy with tyrosine kinase inhibitors (TKIs) in combination with immune checkpoint inhibitors (ICIs).
MATERIALS AND METHODS: This retrospective study included 108 patients (age, 69.4 ± 6.2 years; 38 males) with mRCC who underwent pretreatment [⁶⁸Ga]-PSMA-11 PET/CT and were treated with TKIs plus ICIs between January 2019 and March 2023. Evaluation of the therapeutic response to treatment with TKIs plus ICIs was based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Univariable and multivariable logistic regression analyses were performed to identify the independent predictors of response, defined as complete response (CR) or partial response (PR), to combinations of TKIs and ICIs. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive performance.
RESULTS: Of the 108 patients with mRCC, 12 (11.1%), 24 (22.2%), 45 (41.7%), and 27 (25.0%) achieved CR, PR, stable disease, and progressive disease, respectively. The area under the curve of the cumulative standardized uptake value (SUV)-volume histogram (AUC-CSH) (adjusted odds ratio [aOR], 8.358; P = 0.002) and maximum SUV (SUVmax; aOR, 1.092; P = 0.024) from pretreatment [⁶⁸Ga]-PSMA-11 PET/CT scans and the programmed death-ligand 1 (PD-L1) status (aOR, 6.248; P = 0.026) were identified as independent predictors of treatment response. A predictive model combining AUC-CSH, SUVmax, and PD-L1 status achieved an area under ROC curve (AUROC) value of 0.880 (95% confidence interval: 0.804-0.935), which was significantly higher than the AUROC values of AUC-CSH alone (0.812 [0.726-0.881], P = 0.020), SUVmax alone (0.757 [0.665-0.834], P = 0.031), and PD-L1 status alone (0.637 [0.532-0.733], P < 0.001).
CONCLUSION: AUC-CSH and SUVmax from pretreatment [⁶⁸Ga]-PSMA-11 PET/CT scans were independent predictors of the response to treatment with TKIs plus ICIs in mRCC. When combined with PD-L1 status, they may enhance patient stratification and facilitate clinical decision-making before treatment initiation.
引用
- Chen SH, Wu XH, Qiu QR, et al. Pretreatment [⁶⁸Ga]-PSMA-11 PET/CT to Predict the Response to Treatment With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Korean J Radiol. 2025. PMID: 41078021. doi:10.3348/kjr.2025.0589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。